Stock DNA
Pharmaceuticals & Biotechnology
JPY 262,084 Million (Small Cap)
18.00
NA
0.00%
0.45
1.69%
1.49
Total Returns (Price + Dividend) 
SAWAI GROUP HOLDINGS Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

SAWAI GROUP HOLDINGS Faces Evaluation Shift Amid Mixed Technical Indicators and Declining Profitability
SAWAI GROUP HOLDINGS Co., Ltd. has recently changed its evaluation from 'Not Rated' to 'Sell' due to shifts in technical indicators. The company's long-term performance shows a decline in operating profit and a low return on capital employed, alongside a high debt-equity ratio, indicating financial challenges.
Read More
Sawai Group Holdings Adjusts Valuation Amid Mixed Financial Performance Indicators
SAWAI GROUP HOLDINGS Co., Ltd. has recently experienced a change in its evaluation, reflecting shifts in valuation metrics and technical indicators. While the company's valuation grade is now considered very attractive, its operating profit has declined, and the stock's performance indicators present a mixed outlook.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 8.06% vs -17.21% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 140.03% vs -288.56% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 6.88% vs 8.04% in Mar 2024
YoY Growth in year ended Mar 2025 is -82.86% vs 6.58% in Mar 2024






